Biogen Inc. $BIIB Shares Sold by Nippon Life Global Investors Americas Inc.

Nippon Life Global Investors Americas Inc. reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 3.7% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 132,210 shares of the biotechnology company’s stock after selling 5,010 shares during the period. Biogen makes up approximately 1.2% of Nippon Life Global Investors Americas Inc.’s portfolio, making the stock its 27th biggest holding. Nippon Life Global Investors Americas Inc.’s holdings in Biogen were worth $29,864,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of BIIB. BlackRock Inc. purchased a new position in Biogen during the second quarter valued at approximately $3,453,878,000. Orbimed Advisors LLC purchased a new stake in Biogen in the 1st quarter worth approximately $11,293,000. Tidal Investments LLC boosted its position in Biogen by 9.0% in the 2nd quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company’s stock worth $13,794,000 after purchasing an additional 5,256 shares in the last quarter. Saudi Central Bank grew its stake in shares of Biogen by 89.7% during the 2nd quarter. Saudi Central Bank now owns 10,273 shares of the biotechnology company’s stock worth $2,220,000 after purchasing an additional 4,858 shares during the period. Finally, Handelsbanken Fonder AB grew its stake in shares of Biogen by 12.7% during the 2nd quarter. Handelsbanken Fonder AB now owns 93,236 shares of the biotechnology company’s stock worth $20,145,000 after purchasing an additional 10,510 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

Analyst Ratings Changes

BIIB has been the subject of several analyst reports. Bank of America boosted their target price on shares of Biogen from $219.00 to $244.00 and gave the company a “neutral” rating in a research note on Thursday, October 22nd. Truist Financial reaffirmed a “buy” rating and issued a $260.00 price objective (up from $235.00) on shares of Biogen in a report on Thursday. Royal Bank Of Canada upped their price objective on shares of Biogen from $256.00 to $272.00 and gave the stock an “outperform” rating in a research report on Thursday. Citigroup reissued a “neutral” rating on shares of Biogen in a research note on Wednesday. Finally, Needham & Company LLC raised their target price on Biogen from $256.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

Biogen Price Performance

NASDAQ:BIIB opened at $253.62 on Monday. Biogen Inc. has a one year low of $146.52 and a one year high of $258.78. The stock has a market cap of $37.49 billion, a PE ratio of 108.38, a P/E/G ratio of 2.88 and a beta of 0.10. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.37 and a current ratio of 1.95. The stock has a 50 day moving average price of $227.08 and a 200 day moving average price of $201.04.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The company had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.63 billion. During the same period in the previous year, the business posted $4.81 EPS. Biogen’s revenue was up 10.6% on a year-over-year basis. Equities research analysts expect that Biogen Inc. will post 12.44 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.